文献速递瓣膜病与结构性心脏病

ACURATE neo2瓣膜扩张不全与临床结局:ACURATE IDE试验发现

Valve Underexpansion and Clinical Outcomes With ACURATE neo2: Findings From the ACURATE IDE Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-05-21

ACURATE IDE随机试验中ACURATE neo2未能显示非劣效于对照瓣膜。本事后分析对752例随机队列中植入ACURATE neo2且有可评估术中造影的624例患者进行核心实验室评估,发现21.6%存在瓣膜扩张不全,且与1年死亡、卒中或再住院复合终点升高相关。

要点

  • ACURATE neo2扩张不全发生率为21.6%(135/624)。
  • 基线主动脉瓣叶及瓣环钙化更重与扩张不全独立相关(OR 1.92,95%CI 1.27-2.91,P=0.002)。
  • 扩张不全组1年死亡、卒中或再住院率为18.7%,扩张组为11.8%(P=0.04)。

核心结论

  • ACURATE neo2瓣膜扩张不全与1年死亡、卒中或再住院复合终点风险升高相关。
  • 该分析为事后分析,结果应视为假设生成。

研究设计与样本

  • ACURATE IDE随机对照试验的事后病例回顾与探索性分析。
  • 主随机队列植入ACURATE neo2共752例,其中624例有可评估术中造影并纳入分析。

主要发现

  • 624例中135例(21.6%)存在瓣膜扩张不全。
  • 基线主动脉瓣叶及瓣环钙化更重与扩张不全独立相关(OR 1.92,95%CI 1.27-2.91,P=0.002)。
  • 预扩张频率两组均为100%,后扩张比例26.7% vs 25.2%(P=0.72),球囊尺寸无差异。
  • 扩张不全组1年死亡、卒中或再住院率为18.7%,扩张组为11.8%(P=0.04)。
  • 多变量分析证实扩张不全与复合终点相关(HR 1.92,95%CI 1.27-2.91,P=0.002)。

临床怎么用

  • 术中应关注ACURATE neo2瓣膜扩张情况,尤其对基线瓣叶及瓣环钙化较重的患者。
  • 需进一步研究通过器械设计改进和操作迭代实现最佳瓣膜扩张能否改善临床结局。

局限性

  • 分析为事后性质,结果应视为假设生成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the ACURATE IDE (Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement) randomized controlled trial, ACURATE neo2 failed to show noninferiority to commercially available balloon-expandable (SAPIEN 3/3 Ultra) and self-expanding (Evolut R/PRO/PRO+/FX) valves for the primary endpoint of all-cause mortality, stroke, or rehospitalization at 1 year. A retrospective investigation was undertaken to evaluate potential factors contributing to these outcomes. OBJECTIVES: The goal of this study was to assess the impact of ACURATE neo2 valve expansion on clinical outcomes in the ACURATE IDE trial. METHODS: Post hoc case review identified angulated (nonparallel) commissure posts in a few implanted ACURATE neo2 valves, indicating valve underexpansion. Procedural angiograms for all ACURATE neo2 valves implanted in the trial's main randomized cohort (n = 752) were inspected by an independent core laboratory. An exploratory analysis was performed to evaluate the association between valve expansion and clinical outcomes. RESULTS: Of the 624 patients who underwent implantation with the ACURATE neo2 and had evaluable procedural angiograms, 135 (21.6%) had underexpanded valves. Greater aortic valve leaflet and annulus calcification at baseline was independently associated with ACURATE neo2 valve underexpansion (OR: 1.92; 95% CI: 1.27-2.91; P = 0.002). Procedural techniques, including frequency of predilation (100% in both groups) and postdilation (26.7% vs 25.2%; P = 0.72), and balloon sizing did not differ between the underexpanded and expanded valve groups. ACURATE neo2 underexpansion was associated with a higher 1-year rate of death, stroke, or rehospitalization (underexpanded: 18.7%; expanded: 11.8%; P = 0.04), which was confirmed in a multivariable analysis (HR: 1.92; 95% CI: 1.27-2.91; P = 0.002). CONCLUSIONS: Underexpansion of the ACURATE neo2 valve in the ACURATE IDE study was associated with a higher risk of the composite endpoint of death, stroke, or rehospitalization. Given the post hoc nature of these analyses, the study findings should be considered hypothesis generating. Whether achieving optimal valve expansion of the ACURATE neo2 valve with improvement in device design and procedural iterations will translate into improved clinical outcomes remains to be studied.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Makkar RR, Chakravarty T, Gupta A, et al. Valve Underexpansion and Clinical Outcomes With ACURATE neo2: Findings From the ACURATE IDE Trial. J Am Coll Cardiol. 2025. PMID: 40406945. doi:10.1016/j.jacc.2025.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。